ライフサイエンスコーパス: neuroprotection

1 t the latter could be a promising target for neuroprotection.

2 CS-1, a Ca(2+)-binding protein implicated in neuroprotection.

3 ether inhibition of 15-lipoxygenase provided neuroprotection.

4 f RTN3 expression eliminated cooling-induced neuroprotection.

5 Uhthoff's phenomenon) and provide a route to neuroprotection.

6 at can by itself be effectively targeted for neuroprotection.

7 eal a novel promising therapeutic target for neuroprotection.

8 induction of metabolic changes that provide neuroprotection.

9 at may promote mitochondrial homeostasis and neuroprotection.

10 itivity to mechanical/excitotoxic stress and neuroprotection.

11 states as a new strategy for pharmaceutical neuroprotection.

12 s for its function in neural development and neuroprotection.

13 tau biology that underlies neurotoxicity and neuroprotection.

14 etina and in experimental stroke, leading to neuroprotection.

15 efflux are all essential to NCEH-1-mediated neuroprotection.

16 ra pars compacta neurons and is required for neuroprotection.

17 injury and ischemic preconditioning-mediated neuroprotection.

18 ossible solution for highly efficient ocular neuroprotection.

19 pens minocycline-induced M2 polarization and neuroprotection.

20 hR expression and augments nicotine-mediated neuroprotection.

21 ism by which PGRN oligomeric species provide neuroprotection.

22 echanisms, which may be harnessed to produce neuroprotection.

23 n may uncover new mechanisms and targets for neuroprotection.

24 ter birth and was associated with endogenous neuroprotection.

25 plays a role in immunity, inflammation, and neuroprotection.

26 esults uncover an essential role of TNFR2 in neuroprotection.

27 as a central player transducing ACM-mediated neuroprotection.

28 ow 33.5 degrees C did not provide additional neuroprotection.

29 ted ghrelin-induced AMPK phosphorylation and neuroprotection.

30 3 antagonists may offer future vascular- and neuroprotection.

31 late local microglia in the brain to achieve neuroprotection.

32 on, migration, inflammation, metabolism, and neuroprotection.

33 also suggests that it has a separate role in neuroprotection.

34 argeting neurons rather than glia to produce neuroprotection.

35 toxic-signaling pathway that plays a role in neuroprotection.

36 urvival signalling pathways, thereby driving neuroprotection.

37 sing, therapeutic strategy for photoreceptor neuroprotection.

38 more sensitive functional tests and targeted neuroprotection.

39 ith inflammatory degeneration and TNFR2 with neuroprotection.

40 tion of oxytocin during OGD/R did not induce neuroprotection.

41 s and identify novel therapeutic targets for neuroprotection.

42 es both collateral vessel anatomy and innate neuroprotection.

43 ng that AMPK is a target for ghrelin-induced neuroprotection.

44 Measuring this pathway may help in assessing neuroprotection.

45 NF toward TNFR2, which appears essential for neuroprotection.

46 rgeted therapeutics for RGC subtype-specific neuroprotection.

47 translational modifications in longevity and neuroprotection.

48 suggests a role for HAT/HDAC homeostasis in neuroprotection.

49 and CP-AMPARs as potential drug targets for neuroprotection.

50 trol aberrant synaptic plasticity and afford neuroprotection.

51 geted carnosine polymersomes did not exhibit neuroprotection.

52 levels within 3 h and augmented hypothermic neuroprotection.

53 and to participate in brain homeostasis and neuroprotection.

54 e nervous system, is an important target for neuroprotection.

55 stems and it clearly seems to be involved in neuroprotection.

56 in mitochondrial homeostasis associated with neuroprotection.

57 ication may play a role in estrogen-mediated neuroprotection.

58 adaptive response is the buildup of acquired neuroprotection, a synaptic activity- and gene transcrip

59 deficiency in HIV-infected MDM could provide neuroprotection above that provided by current ART or pr

60 onally, IL-10 and IL-17 are required for the neuroprotection afforded by intestinal dysbiosis.

61 ive astrogliosis, microglial activation, and neuroprotection after cerebral ischemia.

62 have provided evidence that T cell-mediated neuroprotection after CNS injury can occur independently

63 targeting the auto-inhibition of ASIC1a for neuroprotection against acidotoxicity.

64 Thus, there were limits to e2 neuroprotection against amyloidosis, despite its known a

65 on demonstrated effective and well tolerated neuroprotection against cell loss in a zebrafish model o

66 T5 regulates mitochondrial bioenergetics and neuroprotection against cerebral ischemia.

67 lular reactive oxygen species, and exhibited neuroprotection against excitotoxic and oxidative stress

68 rt here that deficiency in bax exerted broad neuroprotection against excitotoxic injury and oxygen/gl

69 cascades mediating potentially compensatory neuroprotection against excitotoxic insult.

70 PA co-treatment-induced Akt-1 activation and neuroprotection against excitotoxicity.

71 Pretreatment with GM1 conferred significant neuroprotection against glutamate-induced cell death.

72 gulation of the synaptic cleft structure and neuroprotection against injury.

73 s and in turn the ability of NPAS4 to confer neuroprotection against KA-induced excitotoxicity to be

74 bilization of endogenous PGC-1alpha to exert neuroprotection against mitochondrial insults.

75 tocin regulated GABAAR subunits in affording neuroprotection against OGD/R injury.

76 mitochondrial unfolded protein response for neuroprotection against rotenone toxicity.

77 Importantly, network neuroprotection against spreading toxicity can be effect

78 thology in vivo while increasing S1R confers neuroprotection against TDP43 toxicity.

79 f the Ser/Thr phosphatase activity and their neuroprotection against the damage caused by okadaic aci

80 Neuroprotection against those hazards is conferred throu

81 e mitochondrial unfolded protein response in neuroprotection against various insults.

82 positive-modulators exerted NMNAT2-specific neuroprotection against vincristine-induced cell death w

83 profen reduces neuroinflammation and induces neuroprotection, alleviating Machado-Joseph disease-asso

84 lysis or impair GTP-binding activity provide neuroprotection although via distinct mechanisms.

85 the TLDc domain is essential for conferring neuroprotection, an important step in understanding the

86 hese results have potential implications for neuroprotection and ameliorating early cognitive and mot

87 resent in foods and beverages and related to neuroprotection and anti-angiogenesis, among other activ

88 compartment that confers cAMP regulation of neuroprotection and axon growth and that may be therapeu

89 odel's spinal cord injury, demonstrating its neuroprotection and axonal regeneration properties.

90 effects than myeloid EP2 ablation, including neuroprotection and broader suppression of inflammatory

91 scribed that PEDF plays an important role in neuroprotection and data provided in the present work re

92 ral diseases and injuries since they provide neuroprotection and differentiate into astrocytes, neuro

93 tential of manipulating BBB permeability for neuroprotection and drug delivery is immense, as we show

94 ffers potential clinical targets to modulate neuroprotection and drug delivery to the CNS.

95 kg) administered acutely post-injury confers neuroprotection and enhances locomotor recovery, and als

96 ecessary to identify strategies for neonatal neuroprotection and for mitigating developmental delays

97 ce subjected to 30 min MCAo led to sustained neuroprotection and functional behavior benefits for at

98 udy investigates the efficacy of daidzein on neuroprotection and functional recovery in a clinically

99 unctional foods and/or nutraceuticals aiming neuroprotection and glucose homeostasis regulation, with

100 cetyl-CoA carboxylase 1 (ACC1), resulting in neuroprotection and increased acetylation of histone H3K

101 activator-induced thrombolysis and to obtain neuroprotection and inhibition of tissue plasminogen act

102 tivariate HR 2.32; 95% CI 1.94 to 2.77), the Neuroprotection and Natural History in Parkinson Plus Sy

103 Overlapping compounds that promoted both neuroprotection and neurite outgrowth were bioinformatic

104 However, NO's dual role in neuroprotection and neurodegeneration may convert to mal

105 atory diseases, which emphasizes its role in neuroprotection and neuroregeneration.

106 information on the delicate balance between neuroprotection and neurotoxicity within which these cel

107 erging mechanisms of loss of opioid-mediated neuroprotection and NMDA-mediated excitotoxicity.

108 contribute to both protein aggregate-related neuroprotection and pathogenesis in neurodegenerative di

109 hways through P2 purinoreceptors, leading to neuroprotection and pathology in the CNS.

110 g and old Tg mice revealed FTY720-associated neuroprotection and reduced aSyn pathology, suggesting t

111 ypes of free radical species, showing strong neuroprotection and reduced infarct size.

112 we further analyzed the effect of FSD-C10 on neuroprotection and remyelination.

113 Cystatin C (CysC) is implicated in neuroprotection and repair in the nervous system in resp

114 e sclerosis (MS), due to their potential for neuroprotection and restoration of function through repa

115 on, both TubA and exogenous FGF-21 conferred neuroprotection and restored mitochondrial trafficking i

116 BMSCs target CXCL12-producing DRGs to elicit neuroprotection and sustained neuropathic pain relief vi

117 ment of ZC3H14 is necessary for PDGF-induced neuroprotection and that this interaction is present in

118 dative phenotype (M2), which associates with neuroprotection and the antiinflammatory ecosystem.

119 pth analyses of the role of PMSC exosomes on neuroprotection and their clinical applications.

120 activation of innate immune cells, enhanced neuroprotection and tissue repair, and improved the succ

121 reas lag behind our current understanding of neuroprotection and vascular biology in general.

122 counterparts (which could be consistent with neuroprotection), and whether better childhood cognitive

123 representing systemic inflammation, impaired neuroprotection, and astrocyte activation associated wit

124 f neuron-derived E2 in astrocyte activation, neuroprotection, and cognitive preservation following is

125 , in the identification of novel targets for neuroprotection, and in improved outcome measures could

126 ndications in treating inflammation, cancer, neuroprotection, and sickle cell disease among many othe

127 oductive health, antifatigue, antioxidation, neuroprotection, antimicrobial activity, anticancer, hep

128 The molecular mechanisms underlying this neuroprotection are unclear; however, DJ-1 has been sugg

129 ficity of these T cells and how they mediate neuroprotection are unknown.

130 sclerosis (MS) therapy largely for potential neuroprotection as it was recognized that FAEs are capab

131 flammatory response and inflammation-related neuroprotection as they display dual beneficial and detr

132 nds that offer significant remyelination and neuroprotection as well as modulation of the immune syst

133 istology showed that recovery was not due to neuroprotection, as expected given the delayed treatment

134 Neuroprotection assessment in PD cellular models of our

135 the therapeutic potential of Nmnat-mediated neuroprotection at advanced stages of HD.

136 Remarkably, besides neuroprotection, BRF110 up-regulates tyrosine hydroxylas

137 Hypothermia shows promise for stroke neuroprotection, but current cooling strategies cause un

138 d-type erythropoietin (EPO) is promising for neuroprotection, but its therapeutic use is limited beca

139 line (ACh) receptors (nAChRs) as targets for neuroprotection, but the underlying neuroprotective mech

140 Neuroprotection by 4-hydroxyestrone involves increased c

141 ch immunomodulatory capabilities can lead to neuroprotection by attenuating microglial activation and

142 These results suggest that LNA-CTGs promote neuroprotection by blocking the detrimental activity of

143 f PPAR-alpha action via fenofibrate leads to neuroprotection by both reducing neuroinflammation and p

144 urthermore, compound 44 demonstrated in vivo neuroprotection by decreasing Abeta1-42-induced toxicity

145 o counteract neurodegeneration is to promote neuroprotection by enhancing myelin regeneration, hence

146 Neuroprotection by Foxp1 is likely to be mediated by the

147 ed using formal neuropathology, which showed neuroprotection by HT throughout the brain, particularly

148 Median neuroprotection by HT was 17.6% (6.8-28.3%), including i

149 In cerebrocortical cell cultures, neuroprotection by IFNbeta against gp120 toxicity is dep

150 novel mechanism by which miR-7 accomplishes neuroprotection by improving mitochondrial health.

151 We report no evidence for neuroprotection by in vivo pretreatment with therapeutic

152 We conclude that HU may offer neuroprotection by mitigating cerebral metabolic stress

153 Therefore, one mechanism of neuroprotection by nicotine is pharmacological chaperoni

154 Sirt1 thus achieves neuroprotection by promoting calcium regulation, and NAD

155 We summarize here how NPD1 elicits neuroprotection by up-regulating c-REL, a nuclear factor

156 otes both forms of AMPAR plasticity and that neuroprotection, by inhibiting ASIC1a, circumvents any f

157 ong more physically fit individuals reflects neuroprotection, by which fitness protects against age-r

158 This neuroprotection carries a physiological cost: reduced ce

159 Although the use of native VIP facilitates neuroprotection, clinical application of the hormone is

160 eived prophylactic early high-dose rhEPO for neuroprotection, compared with infants who received plac

161 TN3 expression is a mediator of RBM3-induced neuroprotection, controlled by novel mechanisms of escap

162 The observed neuroprotection depends on SIRT6 expression in astrocyte

163 novel therapeutic strategy for photoreceptor neuroprotection during acute stress.

164 ypothermic circulatory arrest (HCA) provides neuroprotection during cardiac surgery but entails an is

165 e investigation of SIRT2 activation-mediated neuroprotection during platinum-based cancer treatment.

166 tau pathology underlies the loss of estrogen neuroprotection during the course of AD.

167 The neuroprotection effect of AAV9-GFP-CIP lasted an additio

168 olecular mechanism by which oxytocin affords neuroprotection, especially the interaction between oxyt

169 jection of either lipoxin was sufficient for neuroprotection following acute injury, while inhibition

170 ive astrogliosis, microglial activation, and neuroprotection following an ischemic injury to the brai

171 ptor agonist, IRL-1620, provides significant neuroprotection following cerebral ischemia in rats.

172 ental evidence suggests that T cells mediate neuroprotection following CNS injury; however, the antig

173 ng the resident macrophage of brain provides neuroprotection following diverse microbial infections.

174 interaction with syntaxin 1A, could lead to neuroprotection following ischemic injury in vivo The mi

175 nificantly increased cell viability, induced neuroprotection following ischemic reperfusion, and decr

176 viously been implicated in remyelination and neuroprotection, following a heavy focus on estrogens wi

177 ariables as important clinical indicators of neuroprotection for individuals with UCDs.

178 el will prove valuable in efforts to develop neuroprotection for PD.

179 In preclinical models, STN DBS provides neuroprotection for substantia nigra (SN) dopamine neuro

180 ve stress detoxification pathway and confers neuroprotection from in vitro and in vivo excitotoxicity

181 substantia nigra and confers drug-inducible neuroprotection from oxidative stress.

182 duced functional benefits and the absence of neuroprotection further suggest the presence of nonoverl

183 ate from bench to bedside along the paths of neuroprotection, gene replacement and stem cell-based re

184 AD phenotypes, where CD33 deletion promotes neuroprotection in a manner dependent on TREM2.

185 ter cerebral I/RI and found that it produced neuroprotection in a manner similar to HSPC treatment.

186 rotrophic and the former exhibits remarkable neuroprotection in a mouse acute ischemic stroke model.

187 Glial immune responses provide neuroprotection in a variety of contexts.

188 l engulfment receptor Draper/MEGF10 provides neuroprotection in an AD model of Drosophila (both sexes

189 horibosyltransferase (NAMPT) produced robust neuroprotection in an aggressive CIPN model utilizing th

190 promising in vitro hybrids showed pronounced neuroprotection in an Alzheimer's mouse model at low dos

191 f Kv2.1 can be uniquely modulated to provide neuroprotection in an animal model of acute ischemic str

192 itive function in SAH mice as well as offers neuroprotection in blood- or hemoglobin-treated PCNs and

193 rgeting of OCT2 could be exploited to afford neuroprotection in cancer patients requiring treatment w

194 These findings show that DHA induces neuroprotection in contusion injury.

195 while other mechanisms control PEA-mediated neuroprotection in damaged tissue resulting from traumat

196 tion of ATF6 signaling, which promotes early neuroprotection in HD.

197 cribes the molecular basis of Nmnat-mediated neuroprotection in HD.

198 lay between autophagy, HIF stabilisation and neuroprotection in ischaemic stroke merits further inves

199 portant for the design of clinical trials of neuroprotection in low and mid resource settings.

200 on, leading to neovascularization as well as neuroprotection in mammals.

201 Helium has been shown to provide neuroprotection in mechanical model of acute ischemic st

202 This is associated with neuroprotection in mice, suggesting the promise of this

203 Reports also indicated PGRN-mediated neuroprotection in models of Alzheimer's and Parkinson's

204 odendrocyte survival could be beneficial for neuroprotection in MS.

205 aluating potential therapeutic compounds for neuroprotection in multiple models using elongated treat

206 otransmission may be an important target for neuroprotection in multiple sclerosis.See De Stefano and

207 l-based therapy to promote remyelination and neuroprotection in myelin diseases.

208 f DEDTC, our data do not support its use for neuroprotection in neuropathologies involving oxygen dep

209 ronal maintenance factor and provides potent neuroprotection in numerous preclinical models of neurol

210 nerative genes in RGCs and provide effective neuroprotection in optic neuropathies.SIGNIFICANCE STATE

211 of D-520 in addressing motor dysfunction and neuroprotection in PD and PDD, as well as attenuating de

212 ier of sensitivity to l-DOPA and of nicotine neuroprotection in PD.

213 croglial inflammatory response may result in neuroprotection in PD.

214 roteostasis should inform new strategies for neuroprotection in polyQ-expansion diseases.

215 pment of NAD(+) replenishment strategies for neuroprotection in prion diseases and possibly other pro

216 mitigate alpha-syn pathology and to mediate neuroprotection in proteolipid protein alpha-syn (PLP-SY

217 onstrated that bexarotene was ineffective in neuroprotection in rats in vivo, the results revealed th

218 to modulate brain immune response to achieve neuroprotection in the 6-hydroxydopamine model.

219 metabolism during hibernation and regulating neuroprotection in the brain.

220 -1beta, IL-6, TNFalpha and NOS2 and promotes neuroprotection in the cortical and hippocampal cell pop

221 ong-term analysis demonstrated a significant neuroprotection in the cortical region in the galectin-3

222 complement with EPO-R76E or other drugs for neuroprotection in the setting of traumatic eye injury.

223 est enhanced metabolic plasticity leading to neuroprotection in the SNpc as a result of STN-DBS.

224 ndings suggest that cromolyn sodium provides neuroprotection in the SOD1(G93A) mice by decreasing the

225 The absence of evidence for neuroprotection in this adequately powered trial indicat

226 onists D-519 and D-520 exhibited significant neuroprotection in this assay, while their parent molecu

227 revealed that overexpression of apoD led to neuroprotection in various mouse models of acute stress

228 Finally, QN 23 showed also neuroprotection induction in two in vivo models of cereb

229 Yet targeting this receptor for neuroprotection is challenging due to its broad expressi

230 However, the role of the VEGF gene family in neuroprotection is complex due to the number of biologic

231 Whether this neuroprotection is due to inhibition of apoptosis is unk

232 Neuroprotection is partly reversed by either pharmacolog

233 A hallmark of acquired neuroprotection is the stabilization of mitochondrial st

234 nograft tumors, ANG-induced neurogenesis and neuroprotection, levels of pro-self-renewal transcripts

235 However, neuroprotection may be complemented by the protection of

236 enous activation of the Shh pathway promotes neuroprotection mediated by reactive astrocytes.

237 Complicating the challenges of neuroprotection, misfolded human disease proteins and mi

238 st that the influence of circadian rhythm on neuroprotection must be considered for translational stu

239 synaptic plasticity, neuron-glia interface, neuroprotection, neuroregeneration, and the disseminatio

240 These finding provided evidences of the neuroprotection of EphA2 antagonist and a novel approach

241 ng beneficial effects, including significant neuroprotection of hippocampal CA1 neurons and preservat

242 is is the first report demonstrating in vivo neuroprotection of injured RGCs and optic nerve (ON) by

243 erm trkB blockade abolished STN DBS-mediated neuroprotection of SN neurons following progressive 6-hy

244 Finally, the neuroprotection of the derivatives was evaluated in an i

245 The prominent role of K2P channels in neuroprotection offers novel avenues of research into th

246 s of the hybrids on microglia activation and neuroprotection on HT-22 cells were investigated.

247 y mesenchymal stem cells exerted a paracrine neuroprotection on RGCs.

248 These results indicate an autocrine VEGF neuroprotection on RGCs.

249 and [magnesium] and [preterm or premature or neuroprotection or 'cerebral palsy'].

250 -type lectin receptors on macrophages causes neuroprotection or neurotoxicity, respectively.

251 Unfortunately, there are still no neuroprotection or remyelination strategies available.

252 herapeutic strategies for immune modulation, neuroprotection, or repair of the damaged central nervou

253 ealthy tissue during CSD potentially adds to neuroprotection outside a damaged area, while other mech

254 neuronal viability and conferred a degree of neuroprotection, presumably by counteracting inducible n

255 phate given prior to preterm birth for fetal neuroprotection prevents CP and reduces the combined ris

256 on of systemic inflammation and standardized neuroprotection protocols that limit glial injury could

257 Neuroprotection provided by pharmacological kinase inhib

258 riggered P2Y12 receptor-dependent microglial neuroprotection, regulating neuronal calcium load and fu

259 ina, cellular mechanisms underlying the VEGF neuroprotection remain elusive.

260 but their phagocytic mechanisms and link to neuroprotection remain incompletely characterized.

261 e downstream targets of AID action mediating neuroprotection remained so far unknown.

262 ed neurodegeneration, but the basis of Sirt1 neuroprotection remains elusive.

263 e previous studies indicate that, apart from neuroprotection, ROCK inhibitor Y-27632 can also acceler

264 ly data from trials with the intent of fetal neuroprotection (RR 0.95, 95% CI 0.80 to 1.13, 4,448 bab

265 ues in the molecule as potential targets for neuroprotection.SIGNIFICANCE STATEMENT The importance of

266 lpha1 (NF-alpha1) and has important roles in neuroprotection, stem cell differentiation, and neurite

267 involved in synaptogenesis, axonogenesis and neuroprotection suggesting preservation of neuronal proc

268 assays of BBB permeation, neurotoxicity, and neuroprotection supported the potential of compound 37 a

269 erapies could guide further studies aimed at neuroprotection targeting penumbral tissue, especially i

270 Fingolimod at 1 mg/kg/day provided better neuroprotection than 5 mg/kg/day.

271 Some new developments raise renewed hope for neuroprotection: the appearance of new compounds with mu

272 s in which the intent of treatment was fetal neuroprotection, there was a significant reduction in th

273 n which elevating astrocytic alphaBc confers neuroprotection through a potential non-cell-autonomous

274 rocytes become highly reactive and can exert neuroprotection through the release of neurotrophic fact

275 Ir was not toxic to brain tissue and offered neuroprotection to dopaminergic cells and their terminat

276 cortical neurons, from metabolic support and neuroprotection to the release of cytokines that trigger

277 o modulation of SMN2 encoded transcripts, to neuroprotection, to an expanding repertoire of periphera

278 Blockading P2X7 receptor(P2X7R) provides neuroprotection toward various neurological disorders, i

279 ds could be applied to increase the power of neuroprotection trials while reducing their duration.

280 e considered as an outcome measure in future neuroprotection trials.

281 inated heme protein likely to be involved in neuroprotection, using crystallography under noble gas p

282 on-ionotropic activity of GluN2ARs to confer neuroprotection via Akt activation.

283 IV transmission, but also conferred extended neuroprotection via increased BBB integrity (elevated le

284 ously unrecognized avenue to target HIPK2 in neuroprotection via the Parkin-mediated pathway.SIGNIFIC

285 Neuroprotection was assessed using in vitro and in vivo

286 Diphenyleneiodonium-elicited neuroprotection was associated with the inhibition of mi

287 Moreover, LXB4 neuroprotection was different from that of established L

288 DREAM-related neuroprotection was linked to an interaction between DRE

289 Neuroprotection was not limited to models of demyelinati

290 Neuroprotection was significant in females (p < 0.001),

291 When we sought the basis for 4E-BP1 neuroprotection, we discovered that 4E-BP1 activation pr

292 nhibition of NAMPT blocked P7C3-A20-mediated neuroprotection, whereas supplementation with the NAMPT

293 er injury and identifies a novel strategy of neuroprotection, which might improve the neurological ou

294 g early HIV infection, can provide prolonged neuroprotection, which might significantly delay the ons

295 ed by S1P signaling and can be harnessed for neuroprotection with blood-brain barrier-penetrating S1P

296 atment paradigms can be envisioned combining neuroprotection with IA device treatment to potentially

297 tective immune response in GALTs and confers neuroprotection with improved locomotor recovery.

298 Neuroprotection with P7C3 compounds has been demonstrate

299 These findings support the concept of neuroprotection with phenytoin in patients with acute op

300 activity in SOD1(G93A) mice also resulted in neuroprotection with reduction of misfolded SOD1 levels